The latest MR technology for neuroscience and neuroimaging is now US FDA cleared. SIGNA™ MAGNUS‡ is a cutting-edge MR scanner for both clinical and research users. At the heart of the new system is the MAGNUS head-only, high-performance gradient coil developed in collaboration between GE HealthCare, the United States Department of Defense (DOD) and National Institutes of Health (NIH). Since 2020, a growing number of conference presentations and published papers have further established the broad capabilities in both clinical and academic neuroscience by enabling high-performance gradient coil technology, without the conventional peripheral nerve stimulation (PNS) limitations observed on whole-body scanners.
The unique head-only, asymmetric gradient coil inside SIGNA MAGNUS builds on on previous high-performance gradient technology by delivering 300 mT/m peak amplitude with 750 T/m/s slew rate with the same infrastructure requirements as a clinical 3.0T scanner. SIGNA MAGNUS aims to deliver significant new capabilities for clinicians and researchers working in neuropsychiatry, neurodegenerative disease and neuro-oncology, as well as a broad range of structural and quantitative imaging disciplines.
SIGNA MAGNUS enables clinicians and researchers alike to see further and go deeper. With SIGNA MAGNUS, there will always be more to explore.
‡SIGNA MAGNUS is 510(k) cleared with the US FDA. Not yet CE Marked.
Not available for sale in all regions.
